Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Purple Biotech Ltd ADR (PPBT)

Purple Biotech Ltd ADR (PPBT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,654
  • Shares Outstanding, K 12,845
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,240 K
  • EBIT $ 3 M
  • EBITDA $ 3 M
  • 60-Month Beta 0.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.32
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.12
  • Most Recent Earnings $-0.29 on 11/14/25
  • Next Earnings Date 03/09/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 353.93% (-452.43%)
  • Historical Volatility 99.06%
  • IV Percentile 37%
  • IV Rank 29.21%
  • IV High 1,211.53% on 12/08/25
  • IV Low 0.01% on 09/05/25
  • Expected Move (DTE 5) 0.1275 (16.96%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 1,538
  • Open Int (30-Day) 2,696
  • Expected Range 0.6241 to 0.8791

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.34
  • Number of Estimates 1
  • High Estimate -0.34
  • Low Estimate -0.34
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -30.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7001 +7.36%
on 11/17/25
0.8900 -15.55%
on 12/01/25
-0.0374 (-4.74%)
since 11/12/25
3-Month
0.5528 +35.96%
on 09/25/25
1.4100 -46.70%
on 10/29/25
+0.1811 (+31.74%)
since 09/12/25
52-Week
0.5326 +41.12%
on 09/11/25
5.2000 -85.55%
on 12/31/24
-2.9084 (-79.46%)
since 12/12/24

Most Recent Stories

More News
Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom

As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026.

PPBT : 0.7516 (-8.56%)
Purple Biotech Ltd. Closes $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech raised approximately $2.8 million through a direct offering of American Depositary Shares to advance its oncology therapies.Quiver AI SummaryPurple Biotech Ltd. has successfully completed...

PPBT : 0.7516 (-8.56%)
News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

BCLI : 0.5600 (-4.27%)
LASE : 2.96 (-0.67%)
PPBT : 0.7516 (-8.56%)
BCTX : 9.54 (-7.47%)
STXS : 2.37 (-2.07%)
DMGGF : 0.2001 (-5.17%)
Purple Biotech Ltd. Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech announces a registered direct offering of 472,668 American Depositary Shares, expecting gross proceeds of $2.8 million.Quiver AI SummaryPurple Biotech Ltd. announced a definitive agreement...

PPBT : 0.7516 (-8.56%)
News Movers: Today’s Hottest News That Could Move the Needle Tomorrow

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in...

BCLI : 0.5600 (-4.27%)
LASE : 2.96 (-0.67%)
PPBT : 0.7516 (-8.56%)
BCTX : 9.54 (-7.47%)
STXS : 2.37 (-2.07%)
DCTH : 10.37 (-0.19%)
DMGGF : 0.2001 (-5.17%)
Purple Biotech Stock Hits Nearly 2-Month High On Cancer Drug Trial Success: Retail Thrilled

CM24 targets CEACAM1, a multi-functional membrane glycoprotein that plays a critical role in tumor invasiveness, metastasis, and immune evasion.

PPBT : 0.7516 (-8.56%)
Purple Biotech Ltd. Reports Progress in Phase 2 CM24 Pancreatic Cancer Trial and Biomarker Developments, Financial Results for Q3 2024

Purple Biotech reports progress in pancreatic cancer trial and biomarker findings, with financial results showing reduced losses.Quiver AI SummaryPurple Biotech Ltd., a clinical-stage company focused on...

PPBT : 0.7516 (-8.56%)
Purple Biotech Reports Second Quarter 2022 Financial Results

REHOVOT, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company...

PPBT : 0.7516 (-8.56%)
Purple Biotech Announces Executive Leadership Changes

Gil Efron appointed as Chief Executive Officer Isaac Israel to transition to advisor role, continue as Board member REHOVOT, Israel, July 14, 2022 ...

PPBT : 0.7516 (-8.56%)
Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile

A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer REHOVOT,...

PPBT : 0.7516 (-8.56%)

Business Summary

Purple Biotech Ltd. is a clinical-stage company focusing on therapies to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219 and CM24. Purple Biotech Ltd., formerly known as Kitov Pharma Ltd., is based in TEL AVIV, Israel.

See More

Key Turning Points

3rd Resistance Point 0.8592
2nd Resistance Point 0.8291
1st Resistance Point 0.7903
Last Price 0.7516
1st Support Level 0.7214
2nd Support Level 0.6913
3rd Support Level 0.6525

See More

52-Week High 5.2000
Fibonacci 61.8% 3.4171
Fibonacci 50% 2.8663
Fibonacci 38.2% 2.3155
Last Price 0.7516
52-Week Low 0.5326

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar